![College of Medicine Microbiology](http://s1.studyres.com/store/data/010664771_1-f0d487c1d2081f50fd8c8ab40e65bd73-300x300.png)
College of Medicine Microbiology
... Fomivirsen(Vitravene): The drug binds to viral mRNA within infected cell and prevents it from being translated into viral proteins. This drug active in blocks the replication of cytomegaloviruses(CMV). Methisazone: specifically inhibits the protein synthesis of poxviruses by blocking the translation ...
... Fomivirsen(Vitravene): The drug binds to viral mRNA within infected cell and prevents it from being translated into viral proteins. This drug active in blocks the replication of cytomegaloviruses(CMV). Methisazone: specifically inhibits the protein synthesis of poxviruses by blocking the translation ...
CHM 708
... The median toxic dose; the dose that produces a given toxic response in half the experimental animals or organisms. ...
... The median toxic dose; the dose that produces a given toxic response in half the experimental animals or organisms. ...
Slide 1
... who will be exposed to ill persons during a pandemic. This guidance recommends providing antiviral prophylaxis to those very high exposure risk and high exposure risk employees for the duration of community pandemic outbreaks. ...
... who will be exposed to ill persons during a pandemic. This guidance recommends providing antiviral prophylaxis to those very high exposure risk and high exposure risk employees for the duration of community pandemic outbreaks. ...
life.nthu.edu.tw
... been assembled to show that penicillin is a new and effective type of chemotherapeutic agent, and possesses some properties unknown in any antibacterial substance hitherto described.” • Pfizer - mass production during World War II. ...
... been assembled to show that penicillin is a new and effective type of chemotherapeutic agent, and possesses some properties unknown in any antibacterial substance hitherto described.” • Pfizer - mass production during World War II. ...
Non-competitive inhibition
... (the E-S complex). Non-competitive inhibition is a type of enzyme inhibition where the inhibitor reduces the activity of the enzyme and binds equally well to the enzyme whether or not it has already bound the substrate ...
... (the E-S complex). Non-competitive inhibition is a type of enzyme inhibition where the inhibitor reduces the activity of the enzyme and binds equally well to the enzyme whether or not it has already bound the substrate ...
Advances in antiviral drug discovery and development: Part I
... rapid release or the bioavailability of antivirals remains a major problem. Recently, some novel methods such as the use of heterodimer-loaded erythrocytes [34] with azidothymidine and selfmicroemulsifying systems with acyclovir [35] have shown encouraging results. ...
... rapid release or the bioavailability of antivirals remains a major problem. Recently, some novel methods such as the use of heterodimer-loaded erythrocytes [34] with azidothymidine and selfmicroemulsifying systems with acyclovir [35] have shown encouraging results. ...
H2-receptor antagonists proton pump inhibitors
... renal failure---should be avoided Sucralfate forms a viscous layer in the stomach that may inhibit absorption of other drugs, including phenytoin, digoxin, cimetidine, ketoconazole, and ...
... renal failure---should be avoided Sucralfate forms a viscous layer in the stomach that may inhibit absorption of other drugs, including phenytoin, digoxin, cimetidine, ketoconazole, and ...
4-Metabolic & NA Inhibitor(Lec.1&2)
... – Well absorbed and distributed after oral administration (Iron,Calcium limit absorption ) – Only 20% is metabolized (liver) – Excreted in urine, blocked by probenecid – Effective systemically after oral dose, parenteral forms also available ...
... – Well absorbed and distributed after oral administration (Iron,Calcium limit absorption ) – Only 20% is metabolized (liver) – Excreted in urine, blocked by probenecid – Effective systemically after oral dose, parenteral forms also available ...
Enzyme
... inhibitor disrupts the bonds of the polypeptides which form the enzyme. Therefore the shape of the active site is altered permanently and loses its catalytic properties. ...
... inhibitor disrupts the bonds of the polypeptides which form the enzyme. Therefore the shape of the active site is altered permanently and loses its catalytic properties. ...
QuinTMP_Lowy
... compounds that block folate synthesis. Originally developed in the 1960’s, this combination has remained an important and useful antimicrobial preparation. Chemical Structure: Trimethoprim-sulfamethoxazole combines two agents. Trimethoprim is a pyrimidine that was synthesized as a dihydrofolate redu ...
... compounds that block folate synthesis. Originally developed in the 1960’s, this combination has remained an important and useful antimicrobial preparation. Chemical Structure: Trimethoprim-sulfamethoxazole combines two agents. Trimethoprim is a pyrimidine that was synthesized as a dihydrofolate redu ...
D. To increase stability of the drug
... mutations in the retinoblastoma (RB) pathway, can be used as a safe and efficient vector for the delivery of gene products to the tumor,” said Leonard Post, Ph.D., Onyx senior vice president, research and development. “Onyx’ proprietary technology for inserting the therapeutic gene into the vector i ...
... mutations in the retinoblastoma (RB) pathway, can be used as a safe and efficient vector for the delivery of gene products to the tumor,” said Leonard Post, Ph.D., Onyx senior vice president, research and development. “Onyx’ proprietary technology for inserting the therapeutic gene into the vector i ...
Effectiveness of Oseltamivir in Preventing Influenza in
... family contacts of a primary case compared with sources of infection outside the immediate household.3-5 Prevention of influenza in family contacts is recognized as a means of controlling the spread of influenza within communities.6 The M2 inhibitors amantadine and rimantadine have been used with va ...
... family contacts of a primary case compared with sources of infection outside the immediate household.3-5 Prevention of influenza in family contacts is recognized as a means of controlling the spread of influenza within communities.6 The M2 inhibitors amantadine and rimantadine have been used with va ...
This article was published in an Elsevier journal. The attached... is furnished to the author for non-commercial research and
... for developing high-throughput methodology because they provide information to address issues raised from chemical-based in vitro studies, such as cytotoxicity caused by treatment, drug transport efficiency to the cell, and the effective doses of target compounds, and thus are ideal for developing h ...
... for developing high-throughput methodology because they provide information to address issues raised from chemical-based in vitro studies, such as cytotoxicity caused by treatment, drug transport efficiency to the cell, and the effective doses of target compounds, and thus are ideal for developing h ...
enzymes - La Salle High School
... Lock and Key Model • An enzyme binds a substrate in a region called the active site • Only certain substrates can fit the active site • Amino acid R groups in the active site help substrate bind • Enzyme-substrate complex forms • Substrate reacts to form product ...
... Lock and Key Model • An enzyme binds a substrate in a region called the active site • Only certain substrates can fit the active site • Amino acid R groups in the active site help substrate bind • Enzyme-substrate complex forms • Substrate reacts to form product ...
Amino Acids, Proteins, and Enzymes
... Lock and Key Model • An enzyme binds a substrate in a region called the active site • Only certain substrates can fit the active site • Amino acid R groups in the active site help substrate bind • Enzyme-substrate complex forms • Substrate reacts to form product ...
... Lock and Key Model • An enzyme binds a substrate in a region called the active site • Only certain substrates can fit the active site • Amino acid R groups in the active site help substrate bind • Enzyme-substrate complex forms • Substrate reacts to form product ...
Adjustment of receptor-binding and neuraminidase substrate
... HA-human NA reassortants replicated poorly in embryonated chicken eggs due to the formation of virus aggregates: the avian-type HA, displaying high affinity for the receptor, bound sialylated carbohydrate chains of other virus particles, because human-type NA activity, which is lower than the avian- ...
... HA-human NA reassortants replicated poorly in embryonated chicken eggs due to the formation of virus aggregates: the avian-type HA, displaying high affinity for the receptor, bound sialylated carbohydrate chains of other virus particles, because human-type NA activity, which is lower than the avian- ...
NSAIDs not 4 322
... First choice in inflammatory joint diseases. Naproxen: Related to ibuprofen. More potent. Moderate risk of side effects, longer acting Diclofenac: (Voltaren) It is very potent used in: Rheumatoid arthritis and osteoarthritis Renal colic and postoperative pain Indomethacin (Indocid) Poten ...
... First choice in inflammatory joint diseases. Naproxen: Related to ibuprofen. More potent. Moderate risk of side effects, longer acting Diclofenac: (Voltaren) It is very potent used in: Rheumatoid arthritis and osteoarthritis Renal colic and postoperative pain Indomethacin (Indocid) Poten ...
HIV treatment
... Jordheim, L. P., Durantel, D., Zoulim, F. & Dumontet, C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat. Rev. Drug Discov. 12, 447–464 (2013). Brinkman, K., ter Hofstede, H. J., Burger, D. M., Smeitink, J. A. & Koopmans, P. P. Adverse effects of ...
... Jordheim, L. P., Durantel, D., Zoulim, F. & Dumontet, C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat. Rev. Drug Discov. 12, 447–464 (2013). Brinkman, K., ter Hofstede, H. J., Burger, D. M., Smeitink, J. A. & Koopmans, P. P. Adverse effects of ...
Dosing regimens of selective serotonin reuptake inhibitors (SSRIs
... * Not every SSRI has Australian TGA approval for use for each anxiety disorder; however, there is insufficient evidence to differentiate between efficacy of the individual SSRIs. † Dose orally in the morning after food. Increase dose according to tolerability and patient response. ‡ Doses above 150 ...
... * Not every SSRI has Australian TGA approval for use for each anxiety disorder; however, there is insufficient evidence to differentiate between efficacy of the individual SSRIs. † Dose orally in the morning after food. Increase dose according to tolerability and patient response. ‡ Doses above 150 ...
Click here
... denature the protein abolish enzyme activity, such as high temperatures, extremes of pH or high salt concentrations, while raising substrate concentration tends to increase activity when [S] is low. To find the maximum speed of an enzymatic reaction, the substrate concentration is increased until a ...
... denature the protein abolish enzyme activity, such as high temperatures, extremes of pH or high salt concentrations, while raising substrate concentration tends to increase activity when [S] is low. To find the maximum speed of an enzymatic reaction, the substrate concentration is increased until a ...
or S-warfarin
... carvedilol will increase the efficacy of celecoxib, but barbiturates will reduce it ...
... carvedilol will increase the efficacy of celecoxib, but barbiturates will reduce it ...
Lecture 7 - Antidepressants new 11-12
... Serotonin Antagonists & Reuptake Inhibitors (SARIs) Trazodone Psychtropic drug Weak block of SERT > NET Block 5-HT2 α- blocking effect ( hypotension) Potent H1- blocker( sedation ) ...
... Serotonin Antagonists & Reuptake Inhibitors (SARIs) Trazodone Psychtropic drug Weak block of SERT > NET Block 5-HT2 α- blocking effect ( hypotension) Potent H1- blocker( sedation ) ...
Antiviral Agents: Structural Basis of Action and Rational Design
... requirements. Ideally, an antiviral agent should be extremely potent. Partial inhibition is not acceptable for an antiviral drug. The reason is that limited viral replication under drug pressure allows for the generation of variants that can be selected under treatment. The emergence of resistance i ...
... requirements. Ideally, an antiviral agent should be extremely potent. Partial inhibition is not acceptable for an antiviral drug. The reason is that limited viral replication under drug pressure allows for the generation of variants that can be selected under treatment. The emergence of resistance i ...